Indonesia In-Vitro Diagnostics Market

Plastic Optic Fiber Market Report Thumbnail

Indonesia In-Vitro Diagnostics Market by Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and by End User (Stand Alone, Laboratory, Hospitals, Academics and Medical Schools, Point of Care Testing, and Other End Users) – Opportunity Analysis and Industry Forecast, 2024–2030

Industry: Healthcare | Publish Date: 08-Jul-2024 | No of Pages: 139 | No. of Tables: 104 | No. of Figures: 69 | Format: PDF | Report Code : N/A

  • Facebook
  • Linkedin
  • Whatsapp

Indonesia In-Vitro Diagnostics Market Overview

The Indonesia In-Vitro Diagnostics Market size was valued at USD 1.19 billion in 2023, and is predicted to reach USD 2.04 billion by 2030, at a CAGR of 7.5% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions.

IVD tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology. These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges. 

Increasing Advancements in Healthcare Infrastructure Drives the Market Growth

The advancements in healthcare infrastructure with continuous efforts by both central and regional government in Indonesia, is driving the growth of the in-vitro diagnostics market. According to International Trade Administration, healthcare is a priority on Indonesia’s national agenda, and the central and regional governments continue to build and upgrade healthcare facilities.   Indonesia boasts a total of 3,042 hospitals, with approximately 63% of them privately managed.

Additionally, as of 2022, there are 10,374 public Health Community Centres across the country, offering comprehensive primary healthcare services and vaccinations. With a robust healthcare infrastructure, there will be increased accessibility to diagnostic services, including in-vitro diagnostic tests, for the Indonesian population.

The availability of comprehensive primary healthcare services and vaccinations through public health community centres further ensures that individuals have access to preventive and diagnostic healthcare solutions to meet the needs of patients across various healthcare settings.

Rising Prevalence of Cancer Drives the Market Growth in Indonesia

The prevalence of cancer in the country boosts the demand for advanced diagnostics solutions. According to Global Cancer Observatory Report, in 2022, Indonesia recorded 408,661 new cases of cancer, with 242,988 deaths reported. 
Additionally, there were approximately 1,018,110 prevalent cases of cancer over a 5-year period. The rising incidence of cancer underscores the importance of early detection and timely intervention, driving the demand for advanced diagnostic solutions such as in-vitro diagnostics.

As healthcare providers strive to address the growing burden of cancer in Indonesia, the adoption of in-vitro diagnostics technologies become indispensable for improving patient outcomes and optimizing healthcare delivery.

High Research, Development, and Regulatory Approval Costs Hinder the Market Expansion

High costs associated with research, development, and regulatory approval are significant factors restraining the Indonesia in-vitro diagnostics market expansion. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability.

Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing (POCT) Solutions in IVD Creates Market Opportunity 

Point-of-care testing (POCT) is poised to significantly drive the Indonesia IVD market demand, in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac biomarkers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Competitive Landscape

The promising players operating in the Indonesia in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

Indonesia In-Vitro Diagnostics Market Key Segments

By Type

  • Reagents

  • Instruments

  • Software & Services

By Technique

  • Immunodiagnostics

    • Enzyme-Linked Immunosorbent Assay (ELISA)

    • Rapid Tests

    • Chemiluminescence Immunoassay (CLIA)

    • Enzyme-linked Immunosorbent spot (ELISpot)

    • Radioimmunoassay (RIA)

    • Western Blot

  • Hematology

  • Molecular Diagnostics

    • PCR

    • INAAT 

    • Hybridization 

    • DNA diagnostics 

    • Microarray 

    • Other Molecular Diagnostics

  • Tissue Diagnostics

  • Clinical Chemistry

    • Basic Metabolic Panel 

    • Liver Panel

    • Renal Profile

    • Lipid Profile

    • Thyroid Function Panel 

    • Electrolyte Panel 

    • Speciality Chemicals

  • Other IVD Techniques

By Application

  • Infectious Diseases

  • Cancer

  • Cardiac Diseases

  • Immune System Disorders

  • Nephrological Diseases

  • Gastrointestinal Diseases

  • Others

By End User

  • Stand Alone Laboratory

  • Hospitals

  • Academics and Medical Schools

  • Point of Care Testing

  • Other End Users

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size Value in 2023

USD 1.19 billion

Revenue Forecast in 2030

USD 2.04 billion

Value Growth Rate

CAGR of 7.5% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Billion (USD)

Growth Factors

  • Increasing Advancements in Healthcare Infrastructure Drives the Market Growth.
  • Rising Prevalence of Cancer Drives the Market Growth in Indonesia.

Companies Profiled

10

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

KEY PLAYERS

  • Roche Holding AG

  • Abbott Laboratories

  • Thermo Fisher Scientific Inc.

  • Danaher Corporation

  • Becton, Dickinson and Company

  • Siemens Healthineers AG

  • bioMérieux SA

  • Sysmex Corporation

  • QIAGEN N.V.

  • Bio-Rad Laboratories, Inc.

Bar chart Pie chart Pie chart

Frequently Asked Questions

The Indonesia in-vitro diagnostics market revenue is estimated to reach up to USD 2.04 billion by 2030.

The key players in the Indonesia in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

The Indonesia in-vitro diagnostics market size was estimated at USD 1.19 billion in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the Indonesia IVD market growth.

Introduction of Point-of-Care Testing (POCT) solutions creates opportunities for the Indonesia in-vitro diagnostics market in the coming future.

Download Free Sample

Please Enter Full Name

Please Enter Valid Email ID

Please enter Country Code and Phone No

Please enter message

popular
$2,575
$1,575
$3,875
$2,975

This website uses cookies to ensure you get the best experience on our website. Learn more